# Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia

> **NCT01960387** · PHASE2 · TERMINATED · sponsor: **University of Pittsburgh** · enrollment: 2 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Clofarabine
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT01960387
- **Lead sponsor:** University of Pittsburgh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-10
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** lack of accrual
- **Last updated:** 2016-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01960387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01960387, "Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01960387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*